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pharmacological intervention. There is a need for com-
mon European research efforts, to improve the available 
evidence base and resulting clinical guidance.
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Introduction
Eating is a basic need that is taken for granted by most 
human beings. However, disorders of eating are severe 
mental disorders that are listed among the most common 
chronic illnesses among youth [1] and are often associated 
with high personal, familial, and societal costs. In anorexia 
nervosa (AN), the mortality risk is higher than for other 
serious diseases of adolescence, such as asthma, type 1 dia-
betes, or any other psychiatric disorder [2].
There is some evidence that the age of onset of AN has 
been decreasing in recent decades [3, 4] and that childhood 
and adolescent AN are on the rise [5]. However, despite the 
seriousness and high chronicity of the illness, it remains a 
relatively small research area with significantly fewer pub-
lications than in other fields of mental disorders. Research 
on AN treatment has been particularly neglected. Only 12 
papers among the top 100 cited papers published in the 
AN field address therapeutic strategies [6], although there 
have been some scientific advances that may be translated 
into new treatment methods. It is the aim of this article to 
present a clinically relevant overview of recent progress in 
the treatment of childhood and adolescent AN to support 
early intervention and effective treatment strategies in this 
serious disorder of youth. New developments in the con-
cept and definition of eating disorders, especially of AN, 
as effectuated in DSM-5 [7] and the beta draft of ICD-11 
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In January 2015, we conducted a narrative review of evi-
dence-based medical and psychological treatments for AN 
and subthreshold restricting eating disorders in youth with 
an emphasis on European clinical research, but also includ-
ing key international contributions. We especially, but not 
exclusively searched for clinical research updates from the 
last 2 years. In addition, we systematically compared the 
clinical guidelines of four European countries: Germany 
(German S3-Guidelines, [8]), the Netherlands [9], Spain 
(Clinical Practice Guideline for Eating Disorders, [10] 
and United Kingdom (NICE [11]). In addition, two recent 
reviews of treatment in AN were consulted [12, 13].
Classification and transition from DSM‑IV 
to DSM‑5
An important goal of DSM-5 [7] was the reduction of the 
residual diagnosis “Eating disorder not otherwise speci-
fied” (EDNOS) by, i.a., lowering the threshold for the diag-
nosis of the “classic” eating disorders AN and bulimia ner-
vosa (BN) and by introducing binge eating disorder (BED) 
as a distinct diagnosis. A major change in diagnostic crite-
ria of AN from DSM-IV to DSM-5 was the omission of the 
amenorrhea criterion. This issue is of some importance for 
our patients because the amenorrhea item is not appropri-
ate for premenarchal girls, adolescents on hormonal contra-
ceptives, and males. Several studies have demonstrated that 
females who were still menstruating but fulfilled all other 
criteria for AN closely resemble those who also have amen-
orrhea [14, 15].
For child and adolescent psychiatrists, the weight item 
of the diagnostic criteria (criterion A, [7]) is more distinct 
in referring to pathological vs. “significantly low weight 
in context of […] physical health”, e.g., in referring to the 
effects of starvation. Underweight must be judged in the 
“context of age, sex, developmental trajectory and physi-
cal health” [7], which is, however, still unspecific for the 
somatic changes typical of AN-associated starvation. In 
addition to the rate of weight loss, the NICE and Spanish 
guidelines point to “objective physical signs” and “addi-
tional appropriate laboratory tests” for diagnosing AN, 
especially in children and adolescents. The German and 
Dutch guidelines even recommend specific physical and 
laboratory examinations. For children and adolescents, 
DSM-5 gives no standard measure for the weight crite-
rion. “Guidance regarding how to judge whether a weight 
is significantly low” [16] is provided only for adults in 
DSM-5 [“a body mass index (BMI), calculated as weight in 
kilograms divided by height in m2, lower than 18.5, which 
corresponds to the 10th BMI percentile in US and European 
adult populations”]. To standardize the weight criterion for 
youth in Europe, we would propose the 10th BMI age per-
centile as a sensible weight threshold in minors, which is 
already used in Germany (German guidelines, [8]) and by 
international clinicians [17] (for a more detailed discussion 
and review see [18]). In addition, it would be reasonable 
to establish severity criteria according to BMI percentiles 
(mild, moderate, severe, and extreme, probably correspond-
ing to the 10th, 3rd, 1st, and less than 1st percentile, respec-
tively) similar to those formulated in adult AN [14].
Recent research has reported objective and subjective 
stigmatization of individuals with eating disorders [19, 
20], which is consistently associated with more damage to 
well-being and delayed enrolment in treatment. DSM-IV 
items that implied a deliberate attitude of the patient and 
willful actions (such as “refusal to maintain body weight 
at or above a minimally normal weight for age and height” 
or “denial of the seriousness of low body weight”) were 
replaced by more non-judgmental formulations such as 
“restriction of energy intake relative to requirements” or 
“persistent lack of recognition of the seriousness of the cur-
rent low body weight”.
Moreover, the DSM-IV criteria “intense fear of gain-
ing weight” as well as “a distortion of body image [21] 
are rarely reported by children and young adolescents 
and likely depend on the development of abstract reason-
ing, culture, and the stage of the disease. Thus, clinicians 
treating younger patients may rely on the clinical symp-
tom “persistent behavior that interferes with weight gain” 
(DSM-5 criterion B), which is much more easily detect-
able by caregivers and professionals. The influence of cul-
tural attitudes on body dissatisfaction, especially in Asian 
countries, was emphasized in several recent studies (for a 
review, see [22]).
DSM-5—similar to DSM-IV—distinguishes between 
the restricting and binge eating/purging subtypes of AN. In 
the restricting type, weight loss is primarily accomplished 
by fasting and/or excessive exercising; in the binge eating/
purging type, restrictive eating is interrupted by binging 
and purging, only binging or only purging (such as self-
induced vomiting, laxative abuse, or the use of other weight 
loss-inducing medications).
In DSM-5, atypical AN is subsumed under “Other Spec-
ified Feeding or Eating Disorders”. An eating disorder is 
classified under this category if it does not fulfill all diag-
nostic criteria for AN but still causes “clinically significant 
distress or impairment” in various types of functioning. In 
most cases, a diagnosis of atypical AN is used if the weight 
criterion is not fulfilled.
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In a recent study of adults from the US, no significant 
differences between AN and subthreshold AN were found 
based on self-report or interview measures; the only differ-
ence was that participants with AN reported higher rates of 
binge eating and purging compared with those with sub-
threshold AN and more somatic sequelae, such as lower 
white blood cell counts [23].
The preliminary criteria for AN published in the beta 
draft version of ICD-11 are similar to those in DSM-5 
(http://apps.who.int/classifications/icd11/browse/f/en). 
Analogous to DSM-5, the amenorrhea criterion was omit-
ted. However, the weight criterion for children and adoles-
cents is more specific in ICD-11 than in DSM-5. In contrast 
to a BMI threshold of 18.5 kg/m2 in adults, which corre-
sponds to the 10th BMI percentile of the general popula-
tion, an age-based BMI under the 5th percentile is defined 
as the threshold weight for children and adolescents. In the 
international survey by Cole et al. [24] three cut-offs at age 
18 to define underweight are recommended: a BMI of 18.5 
for grade 1 thinness, a BMI of 17 for grade 2 and a BMI of 
16 for grade 3 thinness. Cole et al. propose a BMI of 17 at 
age 18 (which roughly corresponds to the 5th percentile) 
as a suitable threshold to use as the basis for providing age 
and sex-specific cut-off points for a definition of thinness 
in children and adolescents. However, as grade 1 thinness 
is used for defining the weight threshold for AN in the new 
classification system of DSM-5, it is difficult to understand 
why one would want to choose a lower BMI threshold for 
minors in ICD-11. AN-associated underweight in child-
hood and adolescence may have even more severe health 
effects than in adults, especially on growth and develop-
ment. ICD-11 differentiates between AN with dangerously 
low body weight (<0.1 BMI percentile) and significantly 
low body weight (<5th percentile) in this younger age 
group.
Epidemiology and changes in prevalence 
from DSM‑IV to DSM‑5
The majority of epidemiological surveys report that 
the highest incidence of AN is found in 15–19-year-old 
females, with approximately 40 % of all new cases appear-
ing during this stage of life [5, 25]; for more details, see 
[26]. In a recent UK study based on a primary care regis-
ter [25], an AN incidence rate of 47.5/100,000 15–19-year-
old females/year (according to DSM-IV) was found for 
the year 2009. Incidence rates for AN in this age group 
remained stable between 2000 and 2009; however, there 
was a steady increase in the incidence of EDNOS dur-
ing that time period (note, however, that the diagnosis of 
EDNOS includes atypical AN and other restrictive eating 
disorders). This incidence rate for AN was lower than the 
109.2/100,000 population/year in a Dutch study using a 
primary care sample by the Hoek group [27]. Furthermore, 
in the UK study, 24/100,000 girls had an onset of AN dur-
ing the age range of 10–14 years. In children between 5 and 
12 years of age, the incidence of AN in the UK was esti-
mated at 1.09, with a clear relationship between prevalence 
and increasing age [4].
Recent studies have stated that prevalence rates for eat-
ing disorders differ when using the revised version of 
DSM-5 criteria. When a Portuguese sample of high school 
and university female students (n = 3048) was reclassified 
according to DSM-5 criteria, the point prevalence rates 
were as follows: DSM-IV: 0.59; DSM-5 (with a weight 
threshold of <17.5): 0.69; and DSM-5 (with a weight 
threshold of <18.5): 0.95 [28]. In a very recent Dutch 
community study, the point prevalence of AN was 1.2 in 
females (and thus very similar to the UK rates), whereas 
the lifetime prevalence rate for 19-year-old females was 1.7 
according to the DSM-5 [29].
Incidence and prevalence rates in males
In the UK study based on primary care data, the incidence 
for 15–19-year-old males was 3.8/100,000 person/years, 
which was—similar to girls—also the peak age of inci-
dence for AN. In contrast to females, the peak age of onset 
of EDNOS for males was 10–14 years [25].
The point and lifetime prevalence rates for 19-year-old 
males were 0.1 in the Dutch community study delineated 
above [29] and were thus very similar to those of a former 
investigation described by van Son et al. [27].
Treatment
Most European and international guidelines have empha-
sized a multidisciplinary and multimodal approach address-
ing the medical, nutritional, and psychological needs of the 
affected individual (NICE guidelines, Spanish, Dutch and 
German guidelines; APA [30]). However, with the excep-
tion of outpatient family-based therapy (FBT), there is a 
dearth of controlled studies on the treatment of adolescent 
and childhood AN; hence, most recommendations are still 
based on mainstream clinical opinion with little empiri-
cal standing. This observation holds true for the choice of 
treatment setting and the treatment modality.
Treatment settings
Adolescents with AN are treated in a variety of settings, 
the most important being outpatient treatment, day patient/
partial hospital treatment, inpatient child and adolescent 
psychiatric treatment, and inpatient pediatric treatment. 
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The use of various settings often depends on the health care 
system of the individual country rather than on scientific 
evidence.
Inpatient treatment (IP)
While NICE guidelines recommend outpatient treat-
ment for most patients with AN, the authors make a spe-
cial modification for young patients (“the need for IP and 
the need for urgent weight restoration should be balanced 
alongside the educational and social needs of the young 
person”). Nevertheless, in the UK, admission rates for AN 
have increased substantially in recent years. From 2012 
to 2013, there was a national rise of 8 % in the number of 
admissions to hospital for an eating disorder in compari-
son to the year before, which had already seen an increase. 
Adolescent girls with AN accounted for the vast majority 
of these admissions. In addition, the length of hospital stays 
increased substantially during the last decade (http://www.
hscic.gov.uk/article/3880/Eating-disorders-Hospital-admis-
sions-up-by-8-per-cent-in-a-year).
There are also increasing admission rates for young 
people with AN, especially children, in Germany [31]. In 
Germany, IP remains the treatment of choice for most chil-
dren and adolescents with AN, because, among other rea-
sons, many outpatient therapists do not dare to manage a 
young starved patient. Dutch guidelines propose a “stepped 
care model” offering the “least burdensome, cheapest and 
shortest treatment possible to the patient”, but for AN, “the 
lower levels of stepped care should not be applied”. In the 
US, eating disorders (without differentiating between sub-
types) constitute the ninth most common mental disorder in 
inpatient national hospitals [32].
Different health care politics lead to different clinical 
populations being admitted to hospital. In a study from 
the UK, a continuous drop from a yearly average admis-
sion BMI of 14.1 kg/m2 in 2007 to 13.6 kg/m2 in 2009 was 
observed in adults with AN, which was related to a signifi-
cantly higher likelihood of readmission within 1 year [33]. 
As far as we know, there are no comparable data for ado-
lescents. However, in a recent study including two inpatient 
eating disorder units for adolescents in the UK, BMI in 
13–17-year-olds was only slightly lower than that of a large 
German trial [34, 35] (see below). In Germany, a small but 
significant increase between 2000 and 2009 in the age-
adjusted BMI percentile and absolute BMI in a childhood 
and adolescent sample was found [36, 35].
Only one randomized controlled trial (RCT) from the 
UK (n = 170 adolescents with AN) compared IP with two 
different forms of outpatient care (a specialized eating 
disorder outpatient treatment with emphasis on CBT and 
treatment as usual in child and adolescent mental health 
services) [37]. Although participants improved over the 
two-year follow-up period, there were no differences in 
clinical outcomes between the three groups. The findings 
of this study are difficult to interpret because treatment 
adherence differed substantially between groups, with poor 
treatment uptake in the IP treatment arm. In another recent 
RCT (n = 82) from Australia, adolescent patients were ran-
domized either to hospitalization for medical stabilization 
(mean duration: 3 weeks, mean  %EBW at discharge: 84) 
or for weight restoration (mean duration: 5 weeks, mean 
%EBW at discharge: 92), thus comparing short and slightly 
longer inpatient treatment. Both treatment options were fol-
lowed by outpatient manualized family-based treatment. 
Primary outcome was the number of days spent in hospi-
tal following the first admission. At the 12-month follow-
up, there were no significant differences between groups. 
However, the analysis did not take into account the clus-
ter randomization of the trial nor the distribution of the 
primary outcome variable (the majority of patients had no 
readmissions), thus no strong conclusions can be drawn on 
the comparative merits of these treatment approaches [38].
In the study mentioned above [34], data from patients 
admitted to 14 UK inpatient treatment units (n = 12 for 
adults, n = 2 for adolescents) were collected. In the ado-
lescent subgroup, the change in BMI was twice as large as 
that in the adult sample; there was also a more pronounced 
amelioration in mood and quality of life. In contrast to the 
adults, adolescents’ “confidence to change” as assessed 
by a general scale of motivation to change also increased 
during treatment [34]. This is in line with the results of a 
study carried out in Spain, in which adolescent patients 
significantly improved in BMI, eating attitudes, depressive 
symptomatology, and motivation to change during inpatient 
treatment [39].
In the US, data collected by the National Eating Disor-
ders Quality Improvement Collaborative were used to eval-
uate adolescent medicine-based eating disorder programs. 
Program outcomes did not differ significantly, although the 
proportion of inpatient treatment used in these programs 
varied substantially [40].
The European guidelines studied here agree on several 
criteria for inpatient care in adolescent AN (Table 1). How-
ever, some of the recommendations might be judged con-
troversial. While we deem failure to improve in outpatient 
treatment as a reason for considering admission to hospi-
tal, Gowers et al. (2007) argued that his studies, comparing 
Table 1  Criteria for inpatient care in adolescent AN
1. Insufficient response to outpatient treatment
2. Risk of suicide or severe self-harm
3. Acute medical stabilization necessary
4. Severe social problems or psychiatric comorbidity
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inpatient and outpatient treatment lend little support to a 
transfer from outpatient to inpatient care in the sense of 
a stepped care approach. However, in his study on clini-
cal effectiveness of different treatment settings (2007) less 
than 50 % of the patients randomized to inpatient care actu-
ally received this treatment for at least 4 weeks, so that the 
results of this study might be biased. On the other hand, 
there is growing evidence that a longer duration of illness 
may have a “pernicious effect on physical health, brain 
development and self-efficacy” (for a review see [41]). 
Therefore, all approaches, including hospital admission, 
have to be considered if a patient fails to improve with an 
outpatient approach.
In sum, although adolescents seem to benefit from IP 
more than adults do, the high relapse and readmission rates 
as well as the high financial costs have challenged the view 
that IP is the treatment of choice in moderately to severely 
ill adolescents. In addition, adolescents with AN often do 
not want to be hospitalized and tend to experience hospi-
talization as more coercive than adult patients [42]. Conse-
quently, rates of dropout from inpatient treatment programs 
are up to 25 % [43, 44]. In the French study by Godart [43], 
dropout was significantly higher when the patient was liv-
ing with only one parent, had been hospitalized previously, 
had a lower BMI at admission and was over 18 years [44].
Day patient treatment (DP)
In the four European guidelines mentioned above, DP is 
listed as one possible treatment setting “according to appro-
priate care level” [10]. DP for AN may be an alternative to 
IP or may be useful as an approach following IP [30]. In 
addition to potential cost savings associated with DP, the 
skills that patients obtain while in DP treatment may be 
more easily transferred to the home setting and thus more 
generalizable to everyday life. Moreover, compared with IP, 
DP may be more likely to increase patients’ autonomy and 
self-confidence. In DP, the family is more involved in man-
aging refeeding, which is a strategy that has been shown to 
be effective in the treatment of adolescent AN [45, 46]. In 
addition, during DP, adolescents are able to maintain con-
tact with their peers and to participate in school activities 
and other social networks, thus supporting social compe-
tence. This feature of DP is of considerable importance, as 
patients with AN are known to have a range of social dif-
ficulties [47]. All in all, by keeping patients in touch with 
the challenges of everyday life, DP may ease the transition 
from hospital to the outside world and decrease the subse-
quent risk of rapid relapse.
However, until recently, there were only two small 
uncontrolled studies from Australia and the US demon-
strating preliminary efficacy of a day patient program 
in younger patients [48]. The authors reported that the 
12–18-year-old Australian female patients enrolled in the 
study benefitted from DP, as evidenced by their significant 
weight gain and reduction in eating disorder behavior [49]. 
In a US family-centered day patient program for children 
with a mean age of 13, participants showed significant 
improvement in weight and psychological outcomes at dis-
charge. Unfortunately, there was no follow-up assessment 
in either study [48].
Our own multicenter open-label trial included 172 par-
ticipants from six treatment centers in Germany with ini-
tial admission to hospital for AN. After 3 weeks of inpa-
tient care, the patients were randomly assigned to either IP 
or DP with an identical treatment program in both settings 
[35].
At the 12-month follow-up point, DP was not found to 
be inferior to IP with respect to BMI. In a scale evaluating 
specific eating disorder and global psychological outcomes 
(Morgan & Russell Average Outcome score, [50]), the 
patients in the DP group had better scores in the domains 
of mental well-being and psychosexual adjustment than the 
IP group. In addition, health care costs were significantly 
lower for DP than for IP. The number of serious related 
adverse events (such as suicidal ideation) was low and sim-
ilar in both study groups. Thus, we concluded that the use 
of DP after brief inpatient care was a safe and less costly 
alternative to IP for adolescent patients with non-chronic 
AN and that DP should thus be broadly used in the treat-
ment of AN [51]. A follow-up study that shows even more 
promising results is being prepared.
Outpatient treatment
If receiving outpatient care, patients should obtain psycho-
logical therapy in addition to physical monitoring (NICE 
guidelines). A description of the most frequently applied 
psychological treatments in children and adolescents is 
given below. Most guidelines emphasize that the health 
care professional should be experienced in the treatment 
of eating disorders (NICE and German guidelines). The 
Dutch guidelines primarily recommend a mental health 
care center with expertise in eating disorders because of the 
multidisciplinary treatment capabilities.
Multimodal treatment approach
There is some evidence that a multimodal treatment 
approach in all types of settings (inpatient, day care, and 
outpatient settings) is effective in restoring a healthy body 
weight and better psychological and social functioning 
in patients with AN [52]. In adolescents, this approach is 
mainly based on three components (Table 2).
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Nutritional rehabilitation and principles of weight gain
According to most international guidelines, the restora-
tion of a healthy body weight is one of the central goals 
in the treatment of AN (APA [30]; German and Spanish 
guidelines; NICE guidelines). Weight gain during inpa-
tient or outpatient treatment and the maintenance of weight 
gain after discharge from treatment have been proven to be 
important prognostic factors for the short- and long-term 
course of adolescent AN [53–55]. From the patient’s per-
spective, weight gain is a significant predictor of improved 
psychological outcomes, including global eating disorder 
psychopathology [56].
However, there is widespread variation in the practice of 
defining a “healthy body weight”, i.e., the target weight in 
the treatment of childhood and adolescent AN. In a study 
by Gowers and coworkers [57], 18 eating disorder services 
from the UK, Denmark, Finland, the Netherlands, France, 
Germany, Sweden, Spain, and Ireland provided recom-
mendations for weight targets for a 14-year-old girl. When 
BMI was used, specifications of target weight ranged from 
17.5 to 21 kg/m2 and from the 10th to the 75th age-adjusted 
percentile.
As a rule, a healthy body weight might be defined as the 
weight at which menstruation reoccurs [30]. Note, how-
ever, that this purpose is not mentioned in the four European 
guidelines. Many patients do not resume menses despite 
weight restoration at discharge from treatment [58]. Thus, 
a target weight supported by scientific evidence should be 
determined by the patient’s therapist. In our recent study 
including 172 adolescents, achievement of the 15th to 
20th age-adjusted BMI percentile at discharge was a sig-
nificant positive predictor of the resumption of menses at 
12-month follow-up [58]. Patients who menstruated had 
a mean age-adapted BMI percentile of 24 at follow-up, 
which is very similar to the body weight at the time point 
of resumption of menses observed by Golden et al. [59] 
and roughly corresponds to the 95 % EBW (%Expected 
Body Weight ≙ observed BMI/50th BMI percentile × 100) 
reported by the Le Grange group [60]. In short, an increase 
in BMI to the 25th age-adjusted percentile and weight main-
tenance thereafter are indispensable preconditions for the 
resumption of menses [8]. Note, however, that premorbid 
BMI and the weight at which menstruation ceased are also 
important in determining target weight because there is some 
evidence from our and from an Italian study that patients 
with a higher premorbid BMI will only menstruate at a BMI 
nearer to their original body weight [58, 61, 62]. Younger 
patients and patients with premenarchal onset of AN are at a 
particular risk for protracted amenorrhea [58, 63].
In contrast to a strictly defined target weight, some cli-
nicians prefer a weight range of “around” the 25th age-
adapted BMI percentile.
Expected rate of weight gain
European guidelines differ quite substantially in their rec-
ommendations for weekly weight gain (Table 3), and the 
majority does not distinguish between adolescents and 
adults. Some international authors report that early weight 
gain in adolescent girls during the first weeks of (outpa-
tient) treatment is positively related to outcomes at the end 
of treatment but not to outcomes at 12-month follow-up 
[64].
As far as we know, clinical guidelines do not define 
the caloric intake that is necessary to achieve weight gain 
goals. The NICE guidelines only mention an additional 
amount of 3500–7000 calories per week without differenti-
ating between in- and outpatient treatment or between ado-
lescents and adults. This range is very large, and it is not 
specified which patients may benefit from lower or higher 
caloric intake.
There is a noticeable difference between Euro-
pean and US-American guidelines and their precepts of 
Table 2  Main components of 
multimodal treatment approach 
in adolescent AN
1. Nutritional rehabilitation and nutritional counseling as well as the treatment of medical problems
2. Family (or parent) counseling or family therapy
3. Individual therapy (and, whenever possible, additional group sessions) to correct dysfunctional thoughts 
concerning weight and shape
Table 3  Recommendations for weekly weight gain according to 4 European guidelines
NICE guidelines (no modification for adolescents): 0.5–1.0 kg in an inpatient setting, 0.5 kg in an outpatient setting
Dutch guidelines for adolescents: 0.5–1.0 kg in an outpatient setting, between 0.5 and 1.5 kg in a clinical setting and up to 
2.0 kg in a somatic clinical setting
Spanish guidelines (no modification for adolescents): Ponderal weight gain greater than 0.5 kg with up to 1 kg/week
German guidelines: 0.5–1.0 kg (at the most) in an inpatient setting, 0.2–0.5 kg in an outpatient seeing (no 
strong precept)
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recommended rates of weight gain. The modest weekly 
weight gain of 0.5–1.0 kg during AN inpatient treatment 
practiced in several European countries stands in con-
trast to the recommendations of the US-American guide-
line and various American groups [65, 66]. These authors 
recommend/achieve weight gains of 1–2 kg/week during 
hospitalization.
Refeeding practices
Common practice involves beginning the refeed-
ing process cautiously. Inpatient programs often start 
weight rehabilitation on low-calorie regimens, typically 
30–40 kcal/kg body weight/day or even less in severely 
emaciated patients. Clinicians are afraid of overfeed-
ing their patients with the consequence of cardiac, renal, 
and neurologic complications (the so-called “refeeding 
syndrome”). According to a systematic review based on 
seven observational studies with approximately 400 inpa-
tients, the prescribed energy intake ranges from 1000 to 
>1900 kcal, with a steady increase during the time of 
hospitalization [67]. In the department of the first author, 
we begin refeeding at even lower rates in very emaciated 
patients, which corresponds to the recommendations by an 
expert group of the Royal College of Psychiatrists (Junior 
MARSIPAN http://www.rcpsych.ac.uk/usefulresources/
publications/collegereports/cr/cr168.aspx, accessed 
25.1.2015), who estimate 20 kcal/kg body/weight/day as 
safe, but advise less (5–10 kcal/kg/body weight) for indi-
viduals with very low initial weight or comorbid somatic 
disorders.
However, recent studies have not found any difference 
in the rates of refeeding syndrome between adolescents 
who were started on a low-calorie diet compared with those 
on a high-calorie diet [68, 69]. Hypophosphatemia, a major 
symptom of refeeding syndrome, was instead associated 
with low BMI at intake but was not related to the amount 
of calories consumed [68, 70]. O’Connor and Goldin [71] 
reported the case of a 10-year-old girl with a body weight 
of 24 kg on a refeeding diet of only 600 kcal/day, who 
still developed refeeding syndrome. Thus, some authors 
are concerned that current refeeding practices starting at 
very low energy levels will postpone weight recovery and 
worsen outcomes [72] and have pointed out that “a start 
low, advance slow” regimen could give cause to the “under-
feeding syndrome” [73–75].
Healthy girls between 10 and 13 years of age need 
approximately 50 kcal/kg body weight for their daily 
energy needs, and adolescent girls should consume 
40–45 kcal/kg/body weight [76]. Healthy young women eat 
approximately 30 kcal/kg/body weight per day (range of 
20–40 kcal/kg/day). In contrast, adolescents with AN tend 
to eat no more than 10–20 kcal/kg/day.
Refeeding syndrome primarily develops during the first 
fortnight after starting refeeding [72]. Later in the refeeding 
process, most guidelines recommend a stepwise increase 
of daily intake such as 200 kcal/day [72]. Our American 
colleagues suggest a caloric supply up to 60–100 kcal/kg/
day (in other words, 2400–4000 kcal for a girl of 40 kg and 
3000–6000 kcal for a young woman of 50 kg) [65].
Based on the findings by the Kaye group, patients with 
the restricting type of AN, which is the most prevalent in 
children and adolescents, gain weight more slowly than 
those with the binge/purge type and likely need an even 
higher amount of calories. There is also an evidence that 
the excessive exercise often exhibited by patients with AN 
requires additional calories to gain the same amount of 
weight [65].
In addition to the rate of weight gain, there is a dearth of 
knowledge on macro- and micronutrient needs in adoles-
cent patients with AN. Many of them practice vegetarian-
ism with high fiber intake, low fat intake, normal protein 
levels, and low or normal carbohydrate intake, which often 
do not meet basal nutritional requirements. Moreover, rec-
ommendations for vitamin or mineral requirements despite 
imminent risk of osteoporosis remain vague (NICE and 
Spanish guidelines).
In sum, there is no empirical evidence for an optimal 
weight gain regimen in adolescent AN. Most of the rec-
ommendations are solely based on mainstream clinical or 
expert opinion. Thus, there is an urgent need to gain further 
knowledge—both quantitatively and qualitatively—of the 
nutritional demands of AN patients and to find a common 
approach for optimizing weight restoration practices.
Family‑oriented therapy
All four guidelines emphasize that family members includ-
ing siblings should be involved in the treatment of adoles-
cent and childhood AN. The Maudsley FBT is the most 
established treatment model for adolescents with AN, and 
several RCTs have demonstrated evidence for symptom 
remission and weight rehabilitation. Compared to all other 
treatment approaches in AN, it was assigned the highest 
evidence grade by the NICE guidelines [11]. While the 
first RCTs were conducted in the UK [77–79], the more 
recent ones were performed in the US by the Chicago and 
Stanford groups [17, 80, 81]. FBT is conceptualized as an 
outpatient treatment for medically stable non-chronic ado-
lescents and is built on the assumption that the family is 
the most important resource for the adolescent for weight 
restoration and return to healthy eating patterns. Treatment 
is divided into several overlapping phases. During the first 
phase parental strengths are primarily focused on their 
child´s weight rehabilitation and normalization of eating. 
Parents take care of the adolescent´s food intake, supervise 
1160 Eur Child Adolesc Psychiatry (2015) 24:1153–1167
1 3
meals and restrict physical activity and purging behav-
ior. In the second treatment phase—after having achieved 
a more healthy weight—the adolescent is encouraged to 
regain responsibility over food and eating. In turn, parents 
withdraw from the control of eating; their attention will be 
solicited by more general questions about age-appropriate 
adolescent life and functioning. During the third phase, this 
aspect will be even more emphasized with a focus on nor-
mal adolescent development and increasing autonomy and 
on how the eating disorder has disturbed this process. Last, 
but not least during this last phase, the necessity of relapse 
prevention strategies will be stressed [46, 82].
FBT was compared to individual adolescent-focused 
therapy (AFT) in a large outpatient RCT including 121 
adolescents. At 6- and 12- month follow-up significantly 
more patients in the FBT group achieved remission defined 
as achieving ≥95 % EBW (see above) and eating disorder 
scores within 1 SD of published means [17]. At 12-month 
follow-up, 50 % in the FBT group had achieved full remis-
sion. However, in this trial BMI at admission was higher 
than in several European treatment studies in adolescent 
AN [37, 83, 84]. In addition to psychological treatment 
patients had approximately weekly medical monitoring vis-
its by experienced physicians, and 17 % were taking psy-
chotropic medication at baseline. Moreover, 45 % of the 
Lock et al. sample had been hospitalized before randomisa-
tion, and 26 % were hospitalized during treatment.
At the 4-year follow-up, more probands in the adoles-
cent-focused group had made additional weight gains and 
caught up with the FBT group. Although the result was 
biased by retaining only 65 % of the original probands, 
AFT did not seem to be less effective in the longer run [64, 
73].
In a study from France, a more systemic form of fam-
ily therapy was investigated as an adjunctive interven-
tion to treatment as usual after inpatient treatment. At the 
18-month follow-up, patients who received adjunctive fam-
ily therapy had a better outcome regarding “general out-
come”, BMI and menstrual status [85].
In a very recent trial, FBT was compared to systemic 
family therapy. At the end of treatment and 1-year follow-
up, there were no statistically significant differences regard-
ing body weight and remission rates. FBT was associated 
with a significantly faster weight gain at the beginning of 
treatment, less days spent in hospital and lower treatment 
costs [81]. Patients with more severe obsessive–compulsive 
symptoms had more benefit from systemic family therapy.
Other family-oriented approaches are underway, such 
as a parent-focused treatment as well as stress manage-
ment and skills training programs for parents and carers. 
In the parent-focused program patients are randomly allo-
cated to either parent-focused or conjoint family treatment 
on FBT-basis. While the adolescent patient sees a clinical 
nurse consultant, parents are supported by a mental health 
clinician; in the conjoint therapy group, the whole family is 
seen by a mental health clinician [86]. Caregiver skills pro-
grams were established because of the finding that parents 
and carers of individuals with AN suffer from great objec-
tive and subjective burden [87]. They include self-help and 
web-based interventions [88–90]. Preliminary results dem-
onstrate a reduction of negative experience of caregiving 
and an improvement of depression.
Individual therapy
Although FBT is the treatment of choice for adolescent 
AN, several guidelines also recommend individual meet-
ings with the therapist, e.g., the NICE guidelines (“Chil-
dren and adolescents with AN should be offered individual 
appointments with a healthcare professional separate from 
those with their family members or carers”). In our opin-
ion, this statement is important, as many young patients 
with AN try to protect their parents and may thus be more 
honest in speaking to a professional therapist.
In many European countries individual psychotherapy 
plays an important role as treatment modality in adolescent 
AN, because FBT is under-resourced in many areas, and 
parents are not always able to accompany their children 
regularly.
Individual psychotherapy may be provided on an inpa-
tient or outpatient basis. During the early stages of inpatient 
treatment, a more supportive treatment strategy may be 
necessary because of the mental consequences of malnutri-
tion, such as extreme rigidity and perseveration appearing 
as an overarching preoccupation with weight and shape and 
persistent thinking about calories and food. Somatically 
(and mentally) sufficiently stabilized patients may start 
with a more problem-oriented individual psychotherapy. 
However, there are virtually no controlled studies on spe-
cialist treatments in youth. Some studies include mixed 
samples of adults and adolescents. The psychological inter-
ventions investigated have included adolescent-focused 
therapy (AFT), behavioral therapy, cognitive-behavioral 
therapy (CBT), cognitive analytic therapy, interpersonal 
psychotherapy (IPT), body awareness therapy, and special-
ist supportive clinical management (SSCM), among oth-
ers. Most data suggest that patients improve with specialist 
treatment, but none of these individual approaches has been 
demonstrated as most effective.
AFT was developed at Stanford University and the Uni-
versity of Chicago and is mainly practiced in the US [91, 
92]. It is based on a self-psychology model and consists 
of three treatment phases with an emphasis on adolescent 
developmental tasks. After establishing a reliable therapeu-
tic relationship, the goal of the first phase is to identify the 
patient´s problems and psychological deficits and the way 
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how AN serves to protect the patient against developmen-
tal challenges. In the second phase, the aim of the therapy 
is to help the patient to improve self-efficacy and to try 
to explore school and vocational aims as well as those of 
social identity and processes [92]. In addition, the patient 
is encouraged to gain more independence from the par-
ents. In the third phase, typical developmental problems 
which have to be faced in adolescence are addressed. The 
therapist supports the patient to cope with them in an age-
appropriate manner, thereby improving self-esteem and 
independence.
AFT was compared to FBT in an outpatient RCT includ-
ing 121 adolescents. Although more patients achieved full 
remission in the FBT group at the 12-month follow-up, 
AFT did not seem to be less effective at the four-year fol-
low-up (for more details see above) [64, 73].
Because of the considerable acceptance of CBT, which 
has demonstrated notable improvement in patients with 
BN and other non-restrictive eating disorders, it has been 
enhanced to become a transdiagnostic treatment (CBT 
enhanced, CBT-E). There are two recent European stud-
ies of CBT-E in adolescents with AN, one with outpatients 
[93] and one with inpatients [94]. Detailed descriptions of 
the implementation of CBT-E in adults [95] and adaptation 
for adolescents [96] have been published. Similar to adults, 
CBT-E for adolescents consists of three phases: (1) think-
ing afresh on the current state and maintaining processes of 
the eating disorder, including analyses of pros and cons; (2) 
modification of concerns surrounding weight and shape; 
and (3) maintaining changes and developing strategies to 
handle setbacks. The only difference from CBT-E in adults 
is the routine involvement of parents or caregivers [93]. In 
the first study, outpatients with AN (n = 46) were offered 
40 sessions of CBT-E treatment over 40 weeks followed by 
a 60-week post-treatment phase with only minimal thera-
peutic support. At 60-week follow-up, 28 % of the patients 
had achieved 95 % EBW and a substantial amelioration of 
the eating disorder psychopathology (EDE scores <1 SD 
above the community mean in 76 % of all patients). Two-
thirds of the original sample completed the treatment.
In a second study, CBT-E was adapted for inpatients 
[94]. A total of 27 adolescents participated in the study, 
and 26 completed the treatment. There was a significant 
increase in BMI percentile from the 3rd to the 30th per-
centile and a considerable decrease in specific and global 
eating disorder psychopathology. However, in both studies, 
there was no control group and no comparison with any 
other specific treatment for adolescents, including family-
based treatment.
SSCM combines the principles of supportive psycho-
therapy and clinical management delivered by a clinician 
experienced in the treatment of AN, as it is often practiced 
in general practice or general psychiatric or pediatric hos-
pitals. In addition to the regular monitoring of weight gain, 
the patient receives nutritional education and advice, and 
a target weight is established during treatment. Moreover, 
clinical management includes several components of psy-
choeducation, such as explanations about the symptoms 
and course of the eating disorder. These interventions are 
embedded in a reliable and supportive relationship between 
the clinician and patient to foster an environment of empa-
thy and acceptance [52, 97].
Older adolescents were included in the first SSCM 
study, and the outcomes were compared to those for IPT 
and CBT. While SSCM was superior at the end of treat-
ment, the groups no longer differed at 7-year follow-up 
with respect to physical and cognitive measures [97, 98].
Cognitive remediation therapy
Studies have shown that individuals with eating disorders 
have inefficiencies in neuropsychological functioning, [99–
101]. It has been suggested that neuropsychological deficits 
preexist and underlie the etiology of eating disorders devel-
opment and relapse. Neuropsychological deficits in eat-
ing disorders are set-shifting and weak central coherence. 
Set-shifting concerns the ability to move back and forth 
between multiple tasks, operations or mental sets, and rep-
resents cognitive flexibility. Weak central coherence refers 
to superior detail processing and weak global integration. 
Although both deficits have been demonstrated in adults 
with AN and BN, the picture in adolescents is not so clear. 
Studies range from firm neuropsychological deficits [102] 
to subtle deficits [103] or a mixed picture [104] with a sub-
group of adolescent patients clearly showing an impaired 
cognitive profile [105], that may improve after renutrition 
[106]. A recent systematic review, specifically on set-shift-
ing abilities in children and adolescents, found no overall 
differences between adolescents with AN and healthy con-
trols in relation to commonly used set-shifting tasks [107], 
suggesting that these may be indicative of more prolongued 
illness duration or starvation.
Cognitive remediation therapy (CRT) was devel-
oped with the aim of improving cognitive flexibility and 
thereby improving functioning. The focus of CRT is on 
how patients think, rather than on what patients think. It 
is hypothesized that CRT training works by proliferating 
and refining neural connections and by teaching new, adap-
tive strategies, thus making individuals more flexible in 
the way they think and behave [108]. Preliminary results 
show small to medium effects of CRT on various measures 
of cognitive flexibility in adolescents, either presented in 
groups or individual settings, as an adjunct to other treat-
ments [102, 109].
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Medication
Pharmacotherapy has a very limited evidence base and 
should not be used as the primary or sole treatment strat-
egy. This view is held by the NICE and the Spanish and 
German guidelines. In AN, atypical antipsychotics and 
selective serotonin inhibitors (SSRI) are the most exten-
sively evaluated medications. In recent RCTs and a system-
atic meta-analysis from the US in adults and adolescents, 
adjunctive treatment with second-generation antipsychotics 
did not yield important effects on weight-related outcomes 
or on eating disorder-specific psychopathology.
In a double-blind placebo-controlled study on risperi-
done, 40 adolescent patients were randomized to receive 
either risperidone or placebo in addition to the normal eat-
ing disorder program. After 9 weeks, there were no sig-
nificant differences between the treatment groups in weight 
gain or (with the exception of “interpersonal distrust”) in 
eating disorder psychopathology. There were no adverse 
effects, with the exception of a prolactin increase in the ris-
peridone group [110, 111]. In another placebo-controlled 
study of 20 adolescent females (only 15 of whom com-
pleted the study), the percentage change in median body 
weight did not differ between the two treatment groups. A 
trend of increasing fasting glucose levels and insulin lev-
els was found in those individuals medicated with olan-
zapine [112]. Although both studies lack power because of 
the small sample size, there was no major effect on weight 
development and general or specific psychopathology. In a 
recent systematic review and meta-analysis of the effects 
of olanzapine, risperidone, and amisulpride in both adoles-
cent and adult samples, no significant increase in BMI or 
decrease in the drive for thinness and body dissatisfaction 
was found ([113]; for more details, see Herpertz-Dahlmann 
[114]). In sum, given the uncertainty of effectiveness and 
several adverse effects, the recently observed increase in 
the use of second-generation antipsychotics in AN treat-
ment in the US is difficult to understand [115].
We are well aware that use of medication, particularly 
of olanzapine, might be necessary intermittently in highly 
anxious and agitated patients, who otherwise would resist 
to refeeding [114, 72]. According to the Dutch guidelines, if 
medication is initiated, “olanzapine is the drug of first choice 
in treating AN in children and adolescents.” Usually, side 
effects are mild. Note, however, that all guidelines point to 
possible adverse effects of atypical antipsychotics, such as 
prolonged or abnormal QTc interval, and metabolic changes, 
such as hyperglycemia and hyperlipidemia. It is unclear 
whether very underweight patients with AN are at a particu-
lar risk for developing extrapyramidal symptoms (EPS).
Furthermore, there is no clear evidence of whether and 
under what conditions SSRI may be beneficial in the treat-
ment of AN. Primarily fluoxetine has been examined during 
the weight restoration process and the weight maintenance 
phase of therapy. In two early studies, no effect on weight 
gain was found [116, 117]. In a study of relapse prevention, 
93 weight-restored patients including females 16 years or 
older were enrolled in a controlled multicenter study com-
bining CBT and pharmacotherapy with fluoxetine. As an 
adjunctive medication, fluoxetine was not more effective 
than the placebo, even for depressive and anxiety symp-
toms [118]. Dutch and German guidelines indicate that the 
treatment of depression, obsessive–compulsive symptoms, 
or anxiety with SSRI may be helpful after weight restora-
tion but not during the starvation stage. Weight rehabilita-
tion itself has substantial “antidepressive” and “antiob-
sessive” effects that should be observed before initiating 
pharmacotherapy.
Future studies will hopefully illuminate predictors of 
treatment response or identify different phenotypes of AN 
who might benefit from psychopharmacological treatment. 
Novel pharmaceutical substances targeting hormonal cir-
cuits of appetite control and food intake may also be impor-
tant agents in the future treatment of AN [119]. At present, 
medication should not be the first line treatment, should 
never be used as the only treatment and always has to con-
sider the patient´s nutritional status.
Estrogen supplementation
Our guidelines referring to estrogen administration are no 
longer up to date. The NICE and German guidelines advise 
not to treat children and adolescents with estrogens because 
of premature fusion of epiphyses. However, there is no 
empirical evidence that very low doses of ethinylestradiol 
used in contraceptives lead to premature fusion of epiphy-
sis and thus to short stature.
The Spanish guidelines suggest that “the need to pre-
scribe estrogens to prevent osteoporosis should be carefully 
assessed, given that this medication can hide the presence 
of amenorrhea”. However, estrogen administration alone 
would not be followed by regular menstruation.
Recently, it has become clear that sex hormone replace-
ment therapy, most commonly administered as oral contra-
ceptives containing estrogen/progesterone, does not prevent 
or improve the loss of bone mineral density in girls or young 
women with AN. On the contrary, the regular bleeding that 
occurs with oral contraceptives is misunderstood as the nor-
malization of the menstrual cycle, although it only indicates 
endometrial hormone withdrawal bleeding. Moreover, the eti-
ology of osteoporosis/osteopenia in AN bears no physiologic 
resemblance to that of menopausal women. In a systematic 
review of the literature, the majority of studies did not find 
any benefit of oral contraceptives for bone mineral density in 
AN [120]. Moreover, there is some evidence that the intake of 
oral contraceptives might even worsen bone mineral density. 
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Among others, low levels of insulin-like growth hormone 
factor (IGF-1), which mediates many of the growth hormone 
effects on bones, is a basic cause of reduced bone mass den-
sity in AN. There is some evidence that oral estrogen adminis-
tration is associated with the suppression of IGF-1 production 
by the liver and of androgen levels, which are also essential for 
bone development [121, 122]. In a recent randomized trial by 
Misra et al. [123], transdermal physiologic estrogen replace-
ment was investigated to avoid the use of oral intake. The 
adolescent sample was divided into mature girls with a bone 
age ≥15 years and immature girls with a bone age <15 years, 
who received developmentally adapted doses of estrogen. In 
comparison to the placebo group, spine and hip bone density 
increased in the group treated with transdermally adminis-
tered estrogen [123]. Although this study holds some promise 
in improving bone mineral density in adolescent AN, much 
more research is needed. However, all researchers agree that 
the greatest increase in BMD occurs with the normalization of 
weight and the resumption of menses.
Compulsory treatment
In life-threatening AN, involuntary hospitalization and 
compulsory refeeding may sometimes be necessary to save 
the person’s life. In the UK, NICE [11] guidance recom-
mends that ‘feeding against the will of the patient should 
be an intervention of last resort in the care and management 
of AN’. Further, it is recommended that this ‘is a highly 
specialized procedure requiring expertise in the care and 
management of those with severe eating disorders and the 
physical complications associated with it’ and lastly, that 
there needs to be a clear legal basis for this action and that 
the relevant mental health legislation and associated proce-
dures are followed. A recent EU report discusses criteria, 
standards, and differences in legal frameworks for invol-
untary placement and treatment in different member states 
(http://fra.europa.eu/sites/default/files/fra_uploads/2130-
FRA-2012-involuntary-placement-treatment_EN.pdf).
Two recent systematic reviews [124, 125] have summa-
rized the limited available research evidence on compul-
sory admissions and treatment in AN. It is clear from this 
that these cases tend to be complex with severe ED symp-
toms and high levels of psychiatric comorbidity. While in 
the short-term compulsory treatment is often life saving, the 
longer term effects of this are uncertain. Importantly, qualita-
tive studies suggest that many patients are grateful after the 
event for having been detained and treated against their will.
In summary, the standing of a field is considerably based 
on its evidence for treatment [12]. Although the number of 
RCTs and well-designed studies have increased in the recent 
past, the evidence base for treatment of adolescent AN is still 
limited. Although most clinicians believe that a multidiscipli-
nary and multimodal treatment approach is the most effective 
strategy for restoration of healthy body weight and a fundamen-
tal change in overvaluation of weight and shape, these recom-
mendations are primarily based on mainstream expert opinion 
with little empirical standing. Because of the relative rarity of 
the disorder research should be performed at multiple treatment 
sites and might connect different European countries. When we 
look for advances in treatment, a more “brain-directed therapy” 
[126] emerging from new insights into genetics, neurobiology, 
and cognitive functioning of eating disordered patients might 
help us to develop more effective and individualized strategies 
to overcome this often serious and disabling disease.
Key points
(1) Recent changes of classification criteria in DSM-5 
facilitate a diagnosis of AN in younger subjects, but 
weight criteria and starvation-induced physical signs 
still remain undefined.
(2) Practice guidelines from the four European countries 
Germany, Spain, The Netherlands, and the UK cor-
respond in major recommendations for the treatment 
of AN, but there is no convention, which intensity of 
treatment (inpatient, day patient, outpatient) is neces-
sary at different stages of the illness.
(3) There is no consensus and no evidence—based rec-
ommendation about the most effective way to achieve 
nutritional rehabilitation and whether and how a target 
weight should be set.
(4) Although FBT is recommended as the treatment of 
choice in adolescent AN, there is a dearth of European 
studies on availability and effectiveness.
(5) There is an urgent need for further common European 
research efforts to establish more evidence-based clini-
cal guidelines and recommendations for practice areas 
in the treatment of adolescent AN.
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